Stock Chart

JANX

$16.93 -0.18%
Score: 73.1 HOLD
Pro
Screener
Vol: 0.84x (vs SPY: 0.8x | vs QQQ: 0.8x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Bear Pennant Bearish scenario quality 64/100
Setup invalidates on a close above $17.45 · pole −22% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About JANX - Janux Therapeutics, Inc. Common Stock

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Key Statistics

Market Cap $1B

This JANX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track JANX's price movements with trendlines, gamma walls, and key support/resistance levels.